Title :

Safety of 3-fucosyllactose (3-FL) produced by a derivative strain of <i>Escherichia coli</i> K-12 DH1 as a novel food pursuant to Regulation (EU) 2015/2283.

Author(s) :

Turck, Dominique [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Bohn, Torsten [Auteur]
Castenmiller, Jacqueline [Auteur]
De Henauw, Stefaan [Auteur]
Hirsch-Ernst, Karen Ildico [Auteur]
Maciuk, Alexandre [Auteur]
Mangelsdorf, Inge [Auteur]
Mcardle, Harry J. [Auteur]
Naska, Androniki [Auteur]
Pelaez, Carmen [Auteur]
Pentieva, Kristina [Auteur]
Siani, Alfonso [Auteur]
Thies, Frank [Auteur]
Tsabouri, Sophia [Auteur]
Vinceti, Marco [Auteur]
Aguilera-Gómez, Margarita [Auteur]
Cubadda, Francesco [Auteur]
Frenzel, Thomas [Auteur]
Heinonen, Marina [Auteur]
Prieto Maradona, Miguel [Auteur]
Marchelli, Rosangela [Auteur]
Neuhäuser-Berthold, Monika [Auteur]
Poulsen, Morten [Auteur]
Schlatter, Josef Rudolf [Auteur]
Siskos, Alexandros [Auteur]
Van Loveren, Henk [Auteur]
Colombo, Paolo [Auteur]
Noriega Fernández, Estefania [Auteur]
Knutsen, Helle Katrine [Auteur]

Journal title :

EFSA Journal

Abbreviated title :

EFSA J

Volume number :

21

Pages :

e08026

Publication date :

2023-06-13

ISSN :

1831-4732

English keyword(s) :

3-fucosyllactose
3-FL
human milk oligosaccharide
HMO
HiMO
novel food
safety

English abstract : [en]

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 3-fucosyllactose (3-FL) as a novel food (NF) pursuant to Regulation ...
Show more >Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 3-fucosyllactose (3-FL) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharide (HiMO) 3-FL, but it also contains d-lactose, l-fucose, 3-fucosyllactulose and a small fraction of other related saccharides. The NF is produced by fermentation by a genetically modified strain (Escherichia coli K-12 DH1 MDO MAP1834) of E. coli K-12 DH1 (DSM 4235). The information provided on the manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF to a variety of foods, including infant formula and follow-on formula, food for special medical purposes and food supplements (FS). The target population is the general population. The anticipated daily intake of 3-FL from both proposed and combined (authorised and proposed) uses at their respective maximum use levels in all population categories does not exceed the highest intake level of 3-FL from human milk in infants on a body weight basis. The intake of 3-FL in breastfed infants on a body weight basis is expected to be safe also for other population groups. The intake of other carbohydrate-type compounds structurally related to 3-FL is also considered of no safety concern. FS are not intended to be used if other foods with added 3-FL or human milk are consumed on the same day. The Panel concludes that the NF is safe under the proposed conditions of use.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-02-03T22:32:52Z
2024-03-12T14:04:43Z